Predict your next investment

Aperion Biologics company logo
HEALTHCARE | Elective & Aesthetic Medicine
aperionbiologics.com

See what CB Insights has to offer

Stage

Corporate Minority | Alive

Total Raised

$7M

About Aperion Biologics

Aperion Biologics is a clinical-stage medical device company addressing the need for alternatives to human-based grafts with patented animal based tissue. Aperion Biologics has developed and patented a technique to make animal tissues usable for human applications without causing rejection. The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both "humanizes" and sterilizes the tissues without affecting the biomechanical or biological properties. This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled. Aperion's Z-Process of humanizing and sterilizing tissue can be applicable to a variety of tissues from orthopedic ligaments, bone, and meniscus to valves and vessels to soft tissue grafts for augmentation and repair.

Aperion Biologics Headquarter Location

11969 Starcrest Drive

San Antonio, Texas, 78247,

United States

Latest Aperion Biologics News

Aperion Biologics Files Chapter 7

Dec 7, 2017

Advertisement Privately-held Aperion Biologics (FDBA Crosscart) filed for Chapter 7 protection with the U.S. Bankruptcy Court in the District of Delaware, case number 17-12855. According to BankruptcyData, under a Chapter 7 proceeding, “generally assets are sold by a trustee and the company ceases operation.” Advertisement Aperion is located in San Antonio, Texas, and is presently headed by interim C.F.O. The Company is represented in these proceedings by David M. Klauder of Bielli & Klauder. Aperion Biologics is a commercial-stage medical device company that addresses the significant need for alternatives to human-based sources for tissues to be used in surgical procedures. According to its website, the Company’s lead product, with 14 patents worldwide, is Z-Lig (Reg. ): “an alternative knee ligament reconstruction tissue that is designed to be better for patients and better for surgeons.” According to Court filings, Aperion indicates estimates liabilities at $10 to $50 million, with estimated assets of just $100,000 to $500,000.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aperion Biologics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aperion Biologics is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

M

Medical Devices

7,889 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Aperion Biologics Patents

Aperion Biologics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/9/2004

1/12/2010

Cardiac surgery, Transcription factors, Valvular heart disease, Cardiac surgeons, Implants (medicine)

Grant

Application Date

8/9/2004

Grant Date

1/12/2010

Title

Related Topics

Cardiac surgery, Transcription factors, Valvular heart disease, Cardiac surgeons, Implants (medicine)

Status

Grant

Aperion Biologics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aperion Biologics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.